Dose adjustment of anaesthetics in the morbidly obese.
暂无分享,去创建一个
[1] S L Shafer,et al. Pharmacokinetics, pharmacodynamics, and rational opioid selection. , 1991, Anesthesiology.
[2] P. Toft,et al. Anthropometric Variables as Predictors for Duration of Action of Vecuronium‐Induced Neuromuscular Block , 1994, Anesthesia and analgesia.
[3] D. McClain,et al. Intravenous fentanyl kinetics , 1980, Clinical pharmacology and therapeutics.
[4] I. Mahmood. Prediction of Drug Clearance in Children: Impact of Allometric Exponents, Body Weight, and Age , 2007, Therapeutic drug monitoring.
[5] R. Emilia,et al. Faster wash-out and recovery for desflurane vs sevoflurane in morbidly obese patients when no premedication is used. , 2007, British journal of anaesthesia.
[6] M. Struys,et al. Pharmacokinetic models for propofol--defining and illuminating the devil in the detail. , 2009, British journal of anaesthesia.
[7] I. Fermo,et al. No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients , 2009, European journal of anaesthesiology.
[8] S. Zanotti-Cavazzoni. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial , 2010 .
[9] D. Abernethy,et al. Pediatric Dose Selection , 2010, Clinical pharmacology and therapeutics.
[10] I. Mahmood. Prediction of Clearance, Volume of Distribution and Half‐life by Allometric Scaling and by use of Plasma Concentrations Predicted from Pharmacokinetic Constants: a Comparative Study , 1999, The Journal of pharmacy and pharmacology.
[11] Pancuronium bromide requirement during anesthesia for the morbidly obese. , 1979, Anesthesiology.
[12] S. Harapat,et al. Computer Simulation of the Effects of Alterations in Blood Flows and Body Composition on Thiopental Pharmacokinetics in Humans , 1997, Anesthesiology.
[13] N. Morton,et al. Pharmacokinetic model driven infusion of propofol in children. , 1991, British journal of anaesthesia.
[14] P. White,et al. Dexmedetomidine Infusion During Laparoscopic Bariatric Surgery: The Effect on Recovery Outcome Variables , 2008, Anesthesia and analgesia.
[15] L. Colla,et al. Predictive Performance of the ‘Minto’ Remifentanil Pharmacokinetic Parameter Set in Morbidly Obese Patients Ensuing from a New Method for Calculating Lean Body Mass , 2010, Clinical pharmacokinetics.
[16] G. Drummond. Comparison of decreases in ventilation caused by enflurane and fentanyl during anaesthesia. , 1983, British journal of anaesthesia.
[17] E. Eger,et al. Obesity Modestly Affects Inhaled Anesthetic Kinetics in Humans , 2008, Anesthesia and analgesia.
[18] D. Salazar,et al. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. , 1988, The American journal of medicine.
[19] H. T. Lee. The Dose of Succinylcholine in Morbid Obesity , 2007 .
[20] D. Morgan,et al. Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.
[21] C. Bailey. Long-Duration Low-Flow Sevoflurane and Isoflurane Effects on Postoperative Renal and Hepatic Function , 2002 .
[22] M. Inchiosa,et al. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. , 2005, British journal of anaesthesia.
[23] D. Ray,et al. Induction drug and outcome of patients admitted to the intensive care unit after emergency laparotomy , 2010, European journal of anaesthesiology.
[24] G. Forbes,et al. Lean body mass in obesity. , 1983, International journal of obesity.
[25] R. Matteo,et al. Pharmacodynamics of Vecuronium and Atracurium in the Obese Surgical Patient , 1988, Anesthesia and analgesia.
[26] M. Struys,et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. , 2010, British journal of anaesthesia.
[27] G. Cheymol. Effects of Obesity on Pharmacokinetics , 2000 .
[28] W. Young,et al. Pharmacokinetics of Sufentanil in Obese Patients , 1991, Anesthesia and analgesia.
[29] Johann Greilhuber,et al. Intraspecific Variation in Genome Size: A Critical Reassessment , 1998 .
[30] M. Pai,et al. The Origin of the “Ideal” Body Weight Equations , 2000, The Annals of pharmacotherapy.
[31] R. Shankar,et al. Obesity, obstructive sleep apnoea, and diabetes mellitus: anaesthetic implications. , 2009, British journal of anaesthesia.
[32] Stephen B. Duffull,et al. Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.
[33] K. Tsueda,et al. Pancuronium Bromide Requirement during Anesthesia for the Morbidly Obese , 1978 .
[34] J. Brodsky,et al. Lean Body Weight Scalar for the Anesthetic Induction Dose of Propofol in Morbidly Obese Subjects , 2011, Anesthesia and analgesia.
[35] R N Upton,et al. Cardiac output is a determinant of the initial concentrations of propofol after short-infusion administration. , 1999, Anesthesia and analgesia.
[36] D. Perrier,et al. Thiopental Disposition in Lean and Obese Patients Undergoing Surgery , 1982, Anesthesiology.
[37] Thomas W. Schnider,et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development , 1997 .
[38] B. Murray. When does intraspecific C-value variation become taxonomically significant? , 2005, Annals of botany.
[39] Edward J Boyko,et al. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. , 2009, The Journal of clinical endocrinology and metabolism.
[40] J. P. Adams,et al. Obesity in anaesthesia and intensive care. , 2000, British journal of anaesthesia.
[41] M. Bird. Acute Pain Management: A New Area of Liability for Anesthesiologists , 2007 .
[42] J. Benumof. Obesity, sleep apnea, the airway and anesthesia , 2004, Current opinion in anaesthesiology.
[43] G. Lesser,et al. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. , 1967, Journal of applied physiology.
[44] R. Matteo,et al. Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient , 1992, Anesthesia and analgesia.
[45] E. Bignami,et al. Wash-in and wash-out curves of sevoflurane and isoflurane in morbidly obese patients. , 2002, Minerva anestesiologica.
[46] J. Brodsky,et al. Perioperative management of the obese patient. , 1993, British journal of anaesthesia.
[47] Talmage D. Egan,et al. Remifentanil Pharmacokinetics in Obese versus Lean Patients , 1998, Anesthesiology.
[48] A. Benzer,et al. Pharmacokinetics of Rocuronium Bromide in Obese Female Patients , 2000 .
[49] S. Shafer,et al. The Influence of Method of Administration and Covariates on the Pharmacokinetics of Propofol in Adult Volunteers , 1998, Anesthesiology.
[50] K. Stokholm,et al. Increased glomerular filtration rate and adrenocortical function in obese women. , 1980, International journal of obesity.
[51] AT Murugan,et al. Obesity and respiratory diseases , 2008, Chronic respiratory disease.
[52] James C. Scott,et al. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. , 1990, Anesthesiology.
[53] E. Bulger,et al. Single-dose etomidate for rapid sequence intubation may impact outcome after severe injury. , 2009, The Journal of trauma.
[54] Darrell R. Abernethy,et al. Effect of Obesity on the Pharmacokinetics of Drugs in Humans , 2010, Clinical pharmacokinetics.
[55] P. Kam,et al. Obesity: basic science and medical aspects relevant to anaesthetists , 2005, Anaesthesia.
[56] W. Hoffman,et al. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. , 2006, Journal of clinical anesthesia.
[57] S. Duffull,et al. What is the best size descriptor to use for pharmacokinetic studies in the obese? , 2004, British journal of clinical pharmacology.
[58] T. Pellis,et al. The Effects of Cisatracurium on Morbidly Obese Women , 2004, Anesthesia and analgesia.
[59] Carlos Iribarren,et al. Body Mass Index and Risk for End-Stage Renal Disease , 2006, Annals of Internal Medicine.
[60] C. Bernards,et al. Respiratory and Sleep Effects of Remifentanil in Volunteers with Moderate Obstructive Sleep Apnea , 2009, Anesthesiology.
[61] J. Bennett,et al. Difficult or Impossible Ventilation after Sufentanil‐induced Anesthesia Is Caused Primarily by Vocal Cord Closure , 1997, Anesthesiology.
[62] P. Metnitz,et al. Impact of body mass on incidence and prognosis of acute kidney injury requiring renal replacement therapy , 2010, Intensive Care Medicine.
[63] J. Levron,et al. Performance of Target-controlled Sufentanil Infusion in Obese Patients , 2003, Anesthesiology.
[64] R. Rondanelli,et al. A Clinical and Pharmacokinetic Study , 1983 .
[65] M. Avram,et al. Using Front-end Kinetics to Optimize Target-controlled Drug Infusions , 2003, Anesthesiology.
[66] J. O'Donnell,et al. Desflurane versus sevoflurane for laparoscopic gastroplasty in morbidly obese patients. , 2007, Journal of clinical anesthesia.
[67] R. Farinotti,et al. Propofol Infusion for Maintenance of Anesthesia in Morbidly Obese Patients Receiving Nitrous Oxide A Clinical and Pharmacokinetic Study , 1993, Anesthesiology.
[68] Russell D. Wada,et al. Application of Physiologic Models to Predict the Influence of Changes in Body Composition and Blood Flows on the Pharmacokinetics of Fentanyl and Alfentanil in Patients , 1998, Anesthesiology.
[69] A. J. Gandolfi,et al. Weight, pseudocholinesterase activity, and succinylcholine requirement. , 1983, Anesthesiology.
[70] E. Bignami,et al. Randomized comparison of isoflurane and sevoflurane for laparoscopic gastric banding in morbidly obese patients. , 2001, Journal of clinical anesthesia.
[71] P. Lindholm,et al. Anthropometric Variables as Predictors for Duration of Action of Atracurium-Induced Neuromuscular Block , 1996, Anesthesia and analgesia.
[72] S. Duffull,et al. Caution when lean body weight is used as a size descriptor for obese subjects. , 2002, Clinical pharmacology and therapeutics.
[73] J. McNeill,et al. To scale or not to scale: the principles of dose extrapolation , 2009, British journal of pharmacology.
[74] P. Lumb,et al. Emergence and Recovery Characteristics of Desflurane Versus Sevoflurane in Morbidly Obese Adult Surgical Patients: A Prospective, Randomized Study , 2004, Anesthesia and analgesia.
[75] A. Casati,et al. Anesthesia in the obese patient: pharmacokinetic considerations. , 2005, Journal of clinical anesthesia.
[76] D R Stanski,et al. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. , 1987, The Journal of pharmacology and experimental therapeutics.
[77] L. Colla,et al. Pharmacokinetic Model-Driven Remifentanil Administration in the Morbidly Obese , 2009, Clinical pharmacokinetics.
[78] C. Guilleminault,et al. Opioid medication and sleep-disordered breathing. , 2010, The Medical clinics of North America.
[79] M. Struys,et al. Optimization of desflurane administration in morbidly obese patients: a comparison with sevoflurane using an 'inhalation bolus' technique. , 2003, British journal of anaesthesia.
[80] A. Artru,et al. Long-Duration Low-Flow Sevoflurane and Isoflurane Effects on Postoperative Renal and Hepatic Function , 2001, Anesthesia and analgesia.
[81] Mosteller Rd. Simplified Calculation of Body-Surface Area , 1987 .
[82] H. Shankar,et al. Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. , 2005, Journal of clinical anesthesia.
[83] B V Howard,et al. Relations of Stroke Volume and Cardiac Output to Body Composition: The Strong Heart Study , 2001, Circulation.
[84] R. Weiskopf,et al. Kinetics of desflurane, isoflurane, and halothane in humans. , 1991, Anesthesiology.